Geographic disparity in systemic sclerosis mortality in the United States: 1999

Abstract

Introduction:

Previous studies reported a progressive decrease in the systemic sclerosis mortality rates in the United States from 1959 to 2002. Identification of areas with clusters of higher mortality rates is important to implement targeted interventions. In this study, we aimed to estimate the mortality rates of scleroderma and to analyze its geographic variability at the state level in the United States.

Methods:

Mortality rates of scleroderma from 1999 to 2017 were obtained from the CDC Wonder Underlying Cause of Death database and its query system, using International Classification of Diseases, Tenth Revision codes. Age-adjusted rates were calculated by state and demographics. A linear regression model was applied to evaluate trends over time.

Results:

Over the period studied, a total of 24,525 deaths had scleroderma as the underlying cause of death. The age-adjusted mortality rate was 3.962 per million (95% CI: 3.912–4.012), decreasing progressively from 4.679 (95%CI: 4.423–4.934) in 1999 to 2.993 (95% CI: 2.817–3.170) per million in 2017. The age-adjusted mortality rate was 5.885 (95% CI: 5.802–5.967) and 1.651 (95% CI: 1.604–1.698) per million in females and males, respectively. Per races, the highest age-adjusted mortality rate was in Blacks or African Americans, at 5.703 per million (95% CI: 5.521–5.885), followed by American Indians or Alaska Native at 5.047 per million (95% CI: 4.428–5.667). Clusters of states with higher and lower mortality rates were identified. South Dakota had the highest whereas Hawaii had the lowest mortality rate.

Conclusion:

We found a trend to a progressive decrease in mortality rates of scleroderma during the years of our study. In addition, we found relevant state-by-state variation in mortality with several geographical clusters with higher mortality rates. Further analyses are warranted in order to better understand the factors associated with the observed geographic disparities.

Keywords

Scleroderma systemic sclerosis mortality geographic distribution standardized mortality rate

Get full access to this article

View all access options for this article.

References

Mayes

MD.

Classification and epidemiology of scleroderma. Semin Cutan Med Surg 1998; 17(1): 22–26.

Medsger

Jr Masi

AT.

Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 1971; 74: 714–721.

Steen

Oddis

Conte

et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997; 40(3): 441–445.

Mayes

Lacey

Jr Beebe-Dimmer

et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48(8): 2246–2255.

Michet

Jr McKenna

Elveback

et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985; 60(2): 105–113.

Maricq

Weinrich

Keil

et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32(8): 998–1006.

Mayes

MD.

Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239–254.

Mendoza

Derk

CT.

Systemic sclerosis mortality in the United States: 1999-2002 implications for patient care. J Clin Rheumatol 2007; 13(4): 187–192.

Krishnan

Furst

DE.

Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005; 20(10): 855–861.

10.

Elhai

Meune

Avouac

et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012; 51(6): 1017–1026.

11.

Finch

Rodnan

Buckingham

et al. Bleomycin-induced scleroderma. J Rheumatol 1980; 7: 651–659.

12.

Kim

Yoon

et al. A case of bleomycin-induced scleroderma. J Korean Med Sci 1996; 11: 454–456.

13.

Sharma

Handa

Sood

et al. Bleomycin-induced scleroderma. J Assoc Physicians India 2004; 52: 76–77.

14.

Pedersen

Jensen

Krarup-Hansen

et al. Scleroderma induced by paclitaxel. Acta Oncol 2010; 49: 866–868.

15.

Wanchu

Misra

Limited cutaneous scleroderma induced by pentazocine abuse. J Assoc Physicians India 1995; 43(2): 145.

16.

Attoussi

Faulkner

Oso

et al. Cocaine-induced scleroderma and scleroderma renal crisis. South Med J 1998; 91(10): 961–963.

17.

Haviv

Safadi

Rapid progression of scleroderma possibly associated with penicillamine therapy. Clin Drug Investig 1998; 15(1): 61–63.

18.

Aeschlimann

de Truchis

Kahn

MF.

Scleroderma after therapy with appetite suppressants. Report on four cases. Scand J Rheumatol 1990; 19(1): 87–90.

19.

Silman

Newman

Genetic and environmental factors in scleroderma. Curr Opin Rheumatol 1994; 6: 607–611.

20.

Freire

Alonso

Rivera

et al. Clinical peculiarities of patients with scleroderma exposed to silica: a systematic review of the literature. Semin Arthritis Rheum 2015; 45(3): 294–300.

21.

Zachariae

Systemic scleroderma and scleroderma-like disease after silicone implants. Ugeskr Laeger 1992; 154(32): 2209–2210.

22.

Philen

Posada

Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report. Semin Arthritis Rheum 1993; 23(2): 104–124.

23.

Foti

Leonardi

Rondinone

et al. Scleroderma-like disorders. Autoimmun Rev 2008; 7: 331–339.

24.

Dwyer-Lindgren

Bertozzi-Villa

Stubbs

et al. US county-level trends in mortality rates for major causes of death, 1980-2014. JAMA 2016; 316(22): 2385–2401.

25.

Karalexi

Georgakis

Dessypris

et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol 2017; 35(4): 608–618.

26.

Mokdad

Dwyer-Lindgren

Fitzmaurice

et al. Trends and patterns of disparities in cancer mortality among US counties, 1980-2014. JAMA 2017; 317(4): 388–406.

27.

Vaughan

Quick

Pathak

et al. Disparities in temporal and geographic patterns of declining heart disease mortality by race and sex in the United States, 1973-2010. J Am Heart Assoc 2015; 4(12): e002567.

28.

Howard

Kleindorfer

Cushman

et al. Contributors to the excess stroke mortality in rural areas in the United States. Stroke 2017; 48(7): 1773–1778.

29.

Roth

Dwyer-Lindgren

Bertozzi-Villa

et al. Trends and patterns of geographic variation in cardiovascular mortality among US counties, 1980-2014. JAMA 2017; 317(19): 1976–1992.

30.

Tejada-Vera

Mortality from Alzheimer’s disease in the United States: data for 2000 and 2010. NCHS Data Brief 2013; 116: 1–8.

31.

Tapper

Parikh

ND.

Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. Br Med J 2018; 362: k2817.

32.

Lanska

Kuller

LH.

The geography of stroke mortality in the United States and the concept of a stroke belt. Stroke 1995; 26(7): 1145–1149.

33.

Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying cause of death 1999-2017 on CDC WONDER Online Database, released December, 2018. Data are from the Multiple Cause of Death Files, 1999-2017, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program, http://wonder.cdc.gov/ucd-icd10.html (accessed 13 April 2019).

34.

Arnett

Howard

Tan

et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Arthritis Rheum 1996; 39(8): 1362–1370.

35.

Diegel

Black

Pfau

et al. Case series: rheumatological manifestations attributed to exposure to Libby Asbestiform Amphiboles. J Toxicol Environ Health A 2018; 81(15): 734–747.

36.

Foreman

Naghavi

Ezzati

Improving the usefulness of US mortality data: new methods for reclassification of underlying cause of death. Popul Health Metr 2016; 14: 14.

37.

Thomas

Griffiths

Smeeth

et al. Burden of mortality associated with autoimmune diseases among females in the United Kingdom. Am J Public Health 2010; 100(11): 2279–2287.

38.

Falasinnu

Rossides

Chaichian

et al. Do death certificates underestimate the burden of rare diseases? The example of systemic lupus erythematosus mortality, Sweden, 2001-2013. Public Health Rep 2018; 133(4): 481–488.

Geographic disparity in systemic sclerosis mortality in the United States: 1999–2017

Abstract

Introduction:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References